Endotypes of severe allergic asthma patients who clinically benefit from anti-IgE therapy.
Yu-Chen HuangChih-Ming WengMeng-Jung LeeShu-Min LinChun-Hua WangHan-Pin KuoPublished in: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2018)
Most of the severe allergic asthma patients who benefited from omalizumab treatment were IL-33, IL-25 and TSLP aggravated type 2-high endotype. Rhinosinusitis or with a mixed eosinophilic and neutrophilic airway inflammation should be evaluated in patients who partially responded to omalizumab treatment.